Skip to Main Content

Good morning, everyone, and welcome to another working week. Those of you on our side of the pond had, of course, an extended respite thanks to a federal holiday, and we hope your time was relaxing and invigorating, because that oh-so-familiar routine of deadlines, meetings, and the like has now returned. There is only one thing to do in such situations: reach for a cup of stimulation. Our choice today is macadamia nut. Feel free to join us with whatever flavor you prefer. Or perhaps a spot of tea is in order. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Hope you have a smashing day and do keep in touch …

An AstraZeneca (AZN) immunotherapy won approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors, Reuters tells us. Known as Imfinzi, the drug will be given to non-small cell lung cancer patients with inoperable mid-stage disease that has not spread widely, the first immunotherapy to be approved in this setting. The endorsement gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!